Emergency department (ED)-initiated buprenorphine has proven efficacy, but many patients are reluctant to begin this treatment. This study evaluated SafetyNet, a program using a 2-person, recovery coach and paramedic (RCP) intervention postoverdose to reduce subsequent opioid overdose, engage patients in medications for opioid use disorder (MOUD), and reduce illicit drug use.
Methods:
We conducted a prospective nonrandomized study in individuals who experienced opioid overdoses, received naloxone, but subsequently declined buprenorphine initiation in the ED. Each participant was followed by an RCP team that performed a brief negotiation interview (BNI) to motivate engagement in treatment, peer-recovery coaching to encourage recovery-related activities, and health education around medical concerns by trained paramedics. Participants were followed-up at 30 and 180 days. The primary hypothesized outcome was reduction in overdose events; the secondary hypothesized outcomes were engagement in MOUD and reduction in opioid positive urine tests.
Results:
Eighty-one patients were enrolled and received BNIs; 45 (56%; 95% CI: 44-67) had at least 1 follow-up encounter. Twenty participants (25%; 95% CI: 16-36) had at least 1 overdose during follow-up. Fifty-five participants (68%; 95% CI: 57-78) were confirmed to have engaged in some form of medication treatment. Differences in subsequent overdose events (P = .95), engagement in MOUD (P = .49), and rates of opioid-positive urine toxicology rates within 30 days (P = .44) and between 31 and 180 days (P = .46) were not significantly different when comparing those who did and did not follow-up.
Conclusion:
There were no differences in rates of subsequent overdose, MOUD engagement, or positive urine toxicology screens in our intervention. However, 68% of participants engaged in outpatient MOUD, a treatment associated with fewer overdose events, particularly fatal ones. Substantial limitations occurred due to the COVID pandemic, and sample size estimates were not met. Further research is needed to investigate potential benefits of the SafetyNet program.
Centers for Disease Control and Prevention. Provisional data shows U.S. drug overdose deaths top 100,000 in 2022. 2023. Accessed May 24, 2024. https://blogs.cdc.gov/nchs/2023/05/18/7365/
CaudarellaADongHMilloyMJKerrTWoodEHayashiK.Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51-55.
7.
StooveMADietzePMJolleyD.Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev. 2009;28:347-352.
8.
BradyJEDiMaggioCJKeyesKMDoyleJJRichardsonLDLiG.Emergency department utilization and subsequent prescription drug overdose death. Ann Epidemiol. 2015;25:613-619.e2.
9.
KrawczykNRiveraBDJentVKeyesKMJonesCMCerdaM.Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.
10.
WeinerSGBakerOBernsonDSchuurJD.One-year mortality of patients after emergency department treatment for nonfatal opioid overdose. Ann Emerg Med. 2020;75:13-17.
11.
D’OnofrioGChawarskiMCO’ConnorPG, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med. 2017;32:660-666.
12.
MattickRPBreenCKimberJDavoliM.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. doi:10.1002/14651858.CD002207.pub4.
13.
KakkoJSvanborgKDKreekMJHeiligM.1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668. doi:10.1016/S0140-6736(03)12600-1
14.
FudalaPJBridgeTPHerbertS, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-958. doi:10.1056/NEJMoa022164
15.
MattickRPBreenCKimberJDavoliM.Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209. doi:10.1002/14651858.CD002209.pub2
16.
WakemanSELarochelleMRAmeliO, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
17.
LarochelleMRBernsonDLandT, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169:137-145.
18.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019: 2. https://www.ncbi.nlm.nih.gov/books/NBK541393/
19.
D’OnofrioGO’ConnorPGPantalonMV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313:1636-1644.
20.
MooreKERobertsWReidHHSmithKMZOberleitnerLMSMcKeeSA.Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32-43.
21.
ConneryHS.Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75.
22.
LarochelleMRJonesCMZhangK.Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021. Drug Alcohol Depend. 2023;248:109933.
23.
BassukELHansonJGreeneRNRichardMLaudetA.Peer-delivered recovery support services for addictions in the United States: a systematic review. J Subst Abuse Treat. 2016;63:1-9.
24.
DahlemCHGScaleraMAndersonG, et al. Recovery opioid overdose team (ROOT) pilot program evaluation: a community-wide post-overdose response strategy. Subst Abus. 2021;42:423-427.
25.
PowellKGTreitlerPPetersonNABorysSHallcomD.Promoting opioid overdose prevention and recovery: an exploratory study of an innovative intervention model to address opioid abuse. Int J Drug Policy. 2019;64:21-29.
26.
LieblingEJPerezJJSLittererMMGreeneC.Implementing hospital-based peer recovery support services for substance use disorder. Am J Drug Alcohol Abuse. 2021;47:229-237.
GuoBCorabianPYanC, et al. Community Paramedicine: Program Characteristics and Evaluation [Internet]. Institute of Health Economics; 2017. https://www.ncbi.nlm.nih.gov/books/NBK549083/
29.
LangabeerJRPersseDYatscoAO’NealMMChampagne-LangabeerT.A framework for EMS outreach for drug overdose survivors: a case report of the Houston emergency opioid engagement system. Prehosp Emerg Care. 2021;25:441-448.
30.
MechemCCYatesCARushMSAlleyneASingletonHJBoyleTL.Deployment of alternative response units in a high-volume, urban EMS system. Prehosp Emerg Care. 2020;24:378-384.
31.
D’OnofrioGDegutisLC. Integrating Project ASSERT: a screening, intervention, and referral to treatment program for unhealthy alcohol and drug use into an urban emergency department. Acad Emerg Med. 2010;17(8):903-11.
32.
ScharfBMSabatDJBrothersJMMargolisAMLevyMJ.Best practices for a novel EMS-based naloxone leave behind program. Prehosp Emerg Care. 2021;25:418-426.
33.
CarrollGGWassermanDDShahAA, et al. Buprenorphine field initiation of Rescue treatment by emergency medical services (Bupe FIRST EMS): a case series. Prehosp Emerg Care. 2021;25:289-293.
34.
HernHGGoldsteinDKalminM, et al. Prehospital initiation of buprenorphine treatment for opioid use disorder by paramedics. Prehosp Emerg Care. 2022; 26(6):811-817.
35.
HawkKHoppeJKetchamE, et al. Consensus recommendations on the treatment of opioid use disorder in the emergency department. Ann Emerg Med. 2021;78:434-442.
36.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.American Psychiatric Publishing; 2013.
D’OnofrioGFiellinDAPantalonMV, et al. A brief intervention reduces hazardous and harmful drinking in emergency department patients. Ann Emerg Med. 2012;60:181-192.
40.
BernsteinSLD’OnofrioGRosnerJ, et al. Successful tobacco dependence treatment in low-income emergency department patients: a randomized trial. Ann Emerg Med. 2015;66:140-147.
41.
SantoTJr.ClarkBHickmanM, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78:979-993.
42.
MorganJRBarocasJAMurphySM, et al. Comparison of rates of overdose and hospitalization after initiation of medication for opioid use disorder in the inpatient vs outpatient setting. JAMA Netw Open. 2020;3:e2029676.
43.
MorganJRWangJBarocasJA, et al. Opioid overdose and inpatient care for substance use disorder care in Massachusetts. J Subst Abuse Treat. 2020;112:42-48.
DwyerKWalleyAYLangloisBKMitchellPMNelsonKPCromwellJBernsteinE. Opioid education and nasal naloxone rescue kits in the emergency department. West J Emerg Med. 2015 May;16(3):381-4. https://doi.org/10.5811/westjem.2015.2.24909.
BoguckiSSiddiquiGCarterR, et al. Effect of a home health and safety intervention on emergency department use in the frail elderly: a prospective observational study. West J Emerg Med, 2023;24:522-531.
51.
VilsaintCLKellyJFBergmanBGGroshkovaTBestDWhiteW.Development and validation of a brief assessment of recovery capital (BARC-10) for alcohol and drug use disorder. Drug Alcohol Depend. 2017;177:71-76.
52.
ScottCKDennisML.Results from two randomized clinical trials evaluating the impact of quarterly recovery management checkups with adult chronic substance users. Addiction. 2009;104:959-971.
53.
TetraultJMGreenMLMartinoS, et al. Developing and implementing a multispecialty graduate medical education curriculum on screening, brief intervention, and referral to treatment (SBIRT). Subst Abus. 2012;33:168-181.
54.
ScottCKDennisMLGrellaCE, et al. A community outreach intervention to link individuals with opioid use disorders to medication-assisted treatment. J Subst Abuse Treat. 2019;108:75-81. doi:10.1016/j.jsat.2019.07.001
55.
MeyersRJMillerWRSmithJEToniganJS.A randomized trial of two methods for engaging treatment-refusing drug users through concerned significant others. J Consult Clin Psychol. 2002;70:1182-1185.
56.
WilliamsARMauroCMFengT, et al. Performance measurement for opioid use disorder medication treatment and care retention. Am J Psychiat. 2023;180:454-457.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
